EARS - Auris Medical Holding Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Auris Medical Holding Ltd.

Bahnhofstrasse 21
Zug 6300
41 41 729 71 94

Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Dr. Thomas MeyerFounder, Chairman, CEO & MDN/AN/A1968
Mr. Hernan Levett CPA, CPAChief Financial OfficerN/AN/A1976
Mr. Raoul F. DiasGen. Counsel & Sec.N/AN/AN/A
Colleen A. DeVriesSVP of Cogency Global Inc.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Auris Medical Holding Ltd., a development-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear and vestibular disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 for the intranasal treatment of vertigo; and intranasal betahistine for the prevention of weight gain and drowsiness, which are side effects of various antipsychotic drugs. The company has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Zug, Switzerland.

Corporate Governance

Auris Medical Holding Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.